This study aims to investigate the in vivo dynamic metabolic changes after induced pluripotent stem cells (iPSCs) and iPSC-derived enriched cardiomyocytes (iPSC-CMs) transplantation in a rat model of cardiac ischemia injury. 
INTRODUCTION
Early observations on the mechanisms of ischemic injury focused on relatively simple biochemical and physiological changes which were known to result from interruption of circulation. Subsequent research has shown molecular imaging could potentially identify pathophysiological changes in vivo, which is crucial for evaluating new therapeutic approaches for ischemia injury. Recently, the rapid progress of stem cell technologies has triggered an increasing interest in the use of pluripotent stem cells including embryonic stem cells (ESCs) (1, 2) and induced pluripotent stem cells (iPSCs) (3, 4) in cardiovascular ischemic repair. The new cell type, iPSCs own many similar features of ESCs, and can detour the risk of immune rejection and ethical issues. Although electrocardiographic study has found that iPSC-derived cardiomyocytes (iPSC-CMs) might be an exciting cell source for renewing myocardium in vitro and improving cardiac function (5) , to better understand the in vivo behavior and efficacy of iPSCs and iPSC-CMs transplantation, a noninvasive, sensitive, repeatable and quantitative imaging modality is imperative.
Since positron emission tomography (PET) can be used for both cell trafficking and therapeutic response monitoring in clinical patients, it has been referred as one of the best-suited modalities to evaluate the therapeutic effect of stem cells (6, 7) . Thus, we hypothesized that 18 F-fluorodeoxyglucose ( 18 F-FDG) PET might be useful for evaluate the spatiotemporal dynamic metabolic changes in vivo after transplantation of iPSCs or iPSC-CMs. To verify the above hypothesis, we performed 18 F-FDG micro-PET combined with echocardiography to evaluate the metabolic and functional recovery after iPSCs and iPSC-CMs transplantation in a rat model of myocardial infarction (MI), and confirmed by autoradiography (ARG), immunohistochemical and immunofluorescent analysis.
MATERIALS AND METHODS

Animal Model of MI and Stem Cell Administration
Animal model of MI was established by permanent coronary artery ligation (8) . Enhanced green fluorescent protein (EGFP)-labeled mouse iPSCs and ESCs, H9 human embryonic stem cells (hESCs) or induced pluripotent stem cells (hiPSCs) were cultured as described previously (9) . hESCs and by on October 21, 2017. For personal use only. jnm.snmjournals.org Downloaded from Brief Communications 4 hiPSCs were differentiated into enriched cardiomyocytes (hESC-CMs and hiPSC-CMs) using a 2D monolayer differentiation protocol and maintained in a 5% CO 2 /air environment. Details of generation of stem cells and cell culture conditions were provided in the Supplemental Materials.
To investigate the metabolic change after iPSCs transplantation, 39 adult male Sprague-Dawley rats were divided into 3 groups (n=13 per group): phosphate-buffered saline (PBS) control, mESCs or miPSCs transplantation group. Furthermore, to explore whether iPSC-CMs could improve metabolic function of injured rodent heart, additional 24 rats were divided into 3 groups (n=8 per group; all groups received tacrolimus daily): PBS control, hESC-CM or hiPSC-CM enriched group. Thirty minutes after MI, 14, 21 and 28). The ARG imaging was acquired after the last PET scan.
Immunohistochemical and immunofluorescent Analysis
Primary antibodies against von Willebrand factor (vWF); α-smooth muscle actin (α-SMA); cardiac 
Statistical Analysis
All data were presented as mean ± SD. One-way ANOVA test was performed to analyze the group differences, and Pearson correlation was used to examine the correlation between changes in L/N ratio and LVEF. P < 0.05 was considered as statistical significance.
RESULTS
Findings of micro-PET, echocardiography and ARG
Micro-PET imaging allowed the visualization of 18 F-FDG accumulation throughout the 28-day study period (Fig. 1A and 2A) .
From Day 7-28, glucose metabolism changes (shown as Change of L/N ratio in Fig. 1B and 2B) around the peri-infarct area in both mESCs (P < 0.05) and miPSCs (P < 0.05) groups were significantly higher than that in the PBS control (Fig. 1B) . The glucose metabolism increased gradually in miPSCs group at Day 21 (P < 0.05) and 28 (P < 0.05; Fig. 1B ), compared to the mESCs. Similarly, in Fig. 2B , the glucose metabolism increased significantly from Day 7 to 28 in the hiPSC-CMs (P < 0.05) and hESC-CMs (P < 0.05) groups compared to the PBS group. However, no statistical difference was found between hESC-CMs and hiPSC-CMs enriched groups at Day 7, 14, 21 or 28 (P = 0.170, 0.421, 0.356 or 0.199, respectively).
Similarly, on echocardiographic images, myocardial function (shown as the Change of LVEF) improved significantly in the stem cell transplanted groupsfrom Day 7 to 28 after cell transplantation, compared to the PBS control group (Figs. 1C and 2C ). Compared to the mESCs group, the change of LVEF was significantly lower in miPSCs group at Day 7 (P < 0.05), but increased gradually and became significantly higher from Day 14 to 28 (P < 0.001; Fig. 1D Fig. 2D ).
The micro-PET images were in agreement with the data generated from the ARG studies. During our study period, no teratoma was formed in the heart or other thoracic organs after transplantation of stem cells or stem cell-derived cardiomyocytes.
Immunohistochemical and immunofluorescent Analysis
Immunohistochemical staining demonstrated that the numbers of vWF + and integrated optical density (IOD) α-SMA + cell were significantly higher in the miPSCs or hiPSC-CMs enriched group than those in the PBS control (P < 0.05); however, no statistically significant difference was found between the miPSCs and mESCs groups, or between hiPSC-CMs and hESC-CMs enriched groups (Fig.3A-E) .
The IOD of cTNI or cTNT in the miPSCs or hiPSC-CMs enriched group was significantly higher than that in PBS group (P < 0.05), however, no statistically significant difference were found between the miPSCs and mESCs groups (P = 0.444) or between hiPSC-CMs and hESC-CMs enriched groups (P = 0.688). (2) . Recently, several studies have reported the uses of iPSC-CMs in providing functional benefit after MI, although there has been no consensus about the protective mechanism induced by these differentiated cardiomyocytes (11) . By using cardiac MRI and compared to the non-treated PBS control, Wu JC and his colleagues (12) found that iPSC-CMs promoted cardiac protection and attenuated cardiac remodeling after MI, despite of limited engraftment detected with bioluminescence imaging. In our present study, we found that iPSCs and iPSC-CMs group demonstrated steadily increasing of 18 F-FDG accumulation during the 4-week period, whereas the ESCs group showed higher accumulation only in the earlier stage, indicating that iPSCs, especially the iPSC-CMs may produce a more stable therapeutic response than that of the ESCs or ESC-CMs. Furthermore, our serial immunofluorescent analysis (with 5 time points), transplanted stem cells survived and migrated to the peri-infarct area, expressed the markers of myocardial (cTNI and cTNT), endothelial (vWF), and smooth muscle or myofibroblast cells (α-SMA). This observations suggested that the metabolic and functional recovery after stem cell transplantation might due to transplanted cells differentiating into myocardial cells, secreting paracrine factors, or recruiting peripheral stem cells to the ischemic territory (11) . Interestingly, a very recent study (13) found that hESC-derived myocardial precursors (hMPs) treatment resulted in improvement of cardiac function with smaller infarct size and less wall thinning, induced endogenous angiogenesis with increased capillary density, and reduced apoptosis of host cardiomyocytes as the peri-infarct area within 4 weeks post-MI in mice (13) . by on October 21, 2017. For personal use only. jnm.snmjournals.org Downloaded from
